Compare GSK plc (GSK) vs Rockwell Automation (ROK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Rockwell Automation — how do they compare? GSK plc trades at $52.8 (market cap $101.34B), while Rockwell Automation trades at $464 (market cap $51.40B). The key difference: GSK plc is the larger of the two by market cap, and GSK plc pays the higher dividend (3.49%). Which is the better fit depends on your goals.
| GSK | ROK | |
|---|---|---|
Market Cap | $101.34B | $51.40B |
Sector | Health | Industrials |
52-Week High | $61.18 | $495.08 |
52-Week Low | $36.20 | $328.67 |
Enterprise Value | $121.95B | $55.03B |
Dividend Yield | 3.49% | 1.2% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK's stock trades at $51.25, down 1.99% on the day, with a bearish technical signal from moving averages. Fundamentally, the company shows strong profitability with a 17.78% net margin and 36.42% ROE, supported by a consistent earnings beat history. Recent positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline progress. Valuation appears reasonable with a P/E of 13.71 and EV/EBITDA of 9.16.
The outlook balances a solid core business and promising oncology pipeline against a mixed analyst consensus and near-term cash flow pressures. Key opportunities lie in execution of new drug launches and the upcoming CEO strategy update, while risks include clinical trial setbacks, competitive pressures, and integration of potential acquisitions like Nuvalent.
Rockwell Automation (ROK) trades at $469.77, up 2.02% today, with strong technical momentum and bullish moving average signals. The company has consistently beaten earnings expectations in recent quarters, with Q1 2026 EPS of $3.30 exceeding estimates of $2.88. Revenue remains stable at $8.34B for 2025, though net income margin has declined to 10.41% from previous highs. Recent news highlights the company's leadership in industrial automation and AI integration.
ROK presents a mixed outlook with premium valuation metrics (P/E 47.97) offset by strong analyst support (30.77% buy ratings) and consistent dividend payments. Key risks include margin compression and competitive pressures in industrial automation. The consensus price target of $471.71 suggests limited near-term upside from current levels, requiring sustained earnings growth to justify valuation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Rockwell Automation
Rockwell Automation is a pure-play automation competitor that is the successor entity to Rockwell International, which spun off its former Rockwell Collins avionics segment in 2001. As of fiscal 2021, the firm operates through three segments--intelligent devices, software and control, and lifecycle services. Intelligent devices contains its drives, sensors, and industrial components, software and control contains its information and network and security software, while lifecycle services contains its consulting and maintenance services as well as its Sensia JV with Schlumberger.
Read more on ROK →
